Arye Lipman is a notable inventor based in El Segundo, California. He has made significant contributions to the field of cancer treatment through his innovative work on targeting human prostate-specific membrane antigen (PSMA). With a total of 2 patents, Lipman's inventions are paving the way for advancements in cancer diagnostics and therapies.

Latest Patents

Lipman's latest patents include the development of J591 minibodies and Cys-diabodies for targeting PSMA. In one embodiment, a minibody monomer that binds PSMA is provided. This minibody monomer is encoded by a nucleotide sequence comprising, from N-terminus to C-terminus, an scFv sequence that can bind PSMA, an artificial hinge sequence, and a human IgG CH3 sequence. In another embodiment, a CysDB monomer that binds PSMA is provided. The CysDB monomer may be encoded by a nucleotide sequence comprising, from N-terminus to C-terminus, an scFv sequence that can bind PSMA and a cysteine tail. Additionally, methods for diagnosing or treating cancer associated with PSMA expression in a subject are also provided.

Career Highlights

Arye Lipman is currently associated with Imaginab, Inc., where he continues to innovate in the field of cancer treatment. His work focuses on developing targeted therapies that can improve patient outcomes in oncology.

Collaborations

Some of Lipman's notable coworkers include David T. Ho and Tove Olafsen, who contribute to the collaborative efforts in advancing cancer research and treatment methodologies.

Conclusion

Arye Lipman's contributions to cancer targeting technologies exemplify the impact of innovative thinking in medical science. His work continues to inspire advancements in the diagnosis and treatment of cancer, particularly through the targeting of PSMA.

This text is generated by artificial intelligence and may not be accurate.